Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary delivery of Alpha-1 proteinase inhibitor.” PARI Pharma co-owns the Australian patent, which covers delivery of the inhaled AAT using the PARI eFlow nebulizer.
Kamada CEo David Tsur commented, “The inhaled AAT is currently in a late-stage clinical trial in Europe and Canada for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disease that can cause serious, life threatening lung disease in adults. Securing global protection for our novel technologies and its various methods of use is critically important as we develop highly-purified AAT to address major unmet needs in various pulmonary diseases and advance toward commercial development.”
Read the Kamada press release.
